You are here

Vascularites

Subscribe to flux Vascularites Vascularites
NCBI: db=pubmed; Term=vasculitis AND ((English[lang] OR French[lang]) AND adult[MeSH] AND "last 90 days"[PDat])
Mis à jour : il y a 1 jour 5 heures

The Effects of Adalimumab in Behçet Disease Patients on Clinical Manifestations and on Pro-Inflammatory Cytokines Milieu: Long-Term Follow-Up.

sam, 23/05/2020 - 01:31
Related Articles

The Effects of Adalimumab in Behçet Disease Patients on Clinical Manifestations and on Pro-Inflammatory Cytokines Milieu: Long-Term Follow-Up.

Isr Med Assoc J. 2020 May;22(5):289-293

Authors: Braun-Moscovici Y, Tavor Y, Markovits D, Toledano K, Rozin A, Nahir MA, Balbir-Gurman A

Abstract
BACKGROUND: Behçet's disease is a multi-systemic chronic relapsing inflammatory disease, classified among the vasculitides. The heterogeneity of clinical manifestations challenges the disease management.
OBJECTIVES: To assess efficacy and safety of adalimumab in patients with active persistent Behçet's arthritis who did not respond to disease-modifying anti-rheumatic drugs and to assess the impact of treatment on the cytokine milieu.
METHODS: Our cohort comprised 10 patients with active arthritis who received adalimumab in a 24-week investigator-initiated prospective open-label study. Patients who relapsed within 12 weeks following adalimumab discontinuation could enter a 3-year extension study. The patients underwent a comprehensive assessment including questionnaires and measurement of inflammatory cytokines, adalimumab serum levels, and anti-drug antibodies.
RESULTS: A significant improvement was observed in arthritis, disease activity visual analogue scales, Behçet's disease current activity form, and interleukin-6 (IL-6) levels, but not in health assessment questionnaire and functional assessment of chronic illness therapy fatigue scale questionnaire. Resolution of oral and urogenital ulcers was achieved in all patients. Significant reduction of pain was reported by 40% of patients. The disease relapsed in 9 of 10 patients, within 2-6 weeks following adalimumab discontinuation. Of the 7 patients who continued the study, arthritis was resolved in 5. Two patients with high neutralizing antidrug antibodies titer relapsed.
CONCLUSIONS: Adalimumab treatment achieved a significant improvement in arthritis, mucocutaneous manifestations, and IL-6 levels in all study patients but only 40% reported significant pain reduction. The arthritis relapsed in 90% of patients following adalimumab discontinuation and long-term treatment was required.

PMID: 32378820 [PubMed - indexed for MEDLINE]

Retinal vasculometric characteristics and their associations with polymyalgia rheumatica and giant cell arteritis in a prospective cohort: EPIC-Norfolk Eye Study.

sam, 16/05/2020 - 23:49
Related Articles

Retinal vasculometric characteristics and their associations with polymyalgia rheumatica and giant cell arteritis in a prospective cohort: EPIC-Norfolk Eye Study.

Ann Rheum Dis. 2020 04;79(4):547-549

Authors: Yates M, Welikala R, Rudnicka A, Peto T, MacGregor AJ, Khawaja A, Watts R, Broadway D, Hayat S, Luben R, Barman S, Owen C, Khaw KT, Foster P

PMID: 31784452 [PubMed - indexed for MEDLINE]

Sporadic Abdominal Malady in a Female Mandating a Diagnosis.

sam, 16/05/2020 - 23:49
Related Articles

Sporadic Abdominal Malady in a Female Mandating a Diagnosis.

Am J Med. 2020 04;133(4):e120-e123

Authors: Duffy E, Yan J, Spitz JA, Ireland C, Shah R, Lin CT, Zimmerman J

PMID: 31525339 [PubMed - indexed for MEDLINE]

The Fugitive Finding: Acute Infectious Aortitis in a Patient with Persistent MRSA Bacteremia.

sam, 16/05/2020 - 23:49
Related Articles

The Fugitive Finding: Acute Infectious Aortitis in a Patient with Persistent MRSA Bacteremia.

Am J Med. 2020 04;133(4):434-437

Authors: DeSantis DJ, Russell MC, Keller AW

PMID: 31476290 [PubMed - indexed for MEDLINE]

Case 14-2020: A 37-Year-Old Man with Joint Pain and Eye Redness.

mer, 13/05/2020 - 23:38
Related Articles

Case 14-2020: A 37-Year-Old Man with Joint Pain and Eye Redness.

N Engl J Med. 2020 04 30;382(18):1750-1758

Authors: Sobrin L, Stone JH, Huang AJ, Niles JL, Nazarian RM

PMID: 32348648 [PubMed - indexed for MEDLINE]

Innovative Solutions and Insights to Phlebitis Prevention.

mer, 13/05/2020 - 23:38
Related Articles

Innovative Solutions and Insights to Phlebitis Prevention.

Am J Med. 2020 03;133(3):261-264

Authors: Heng SY, Yap RT, McGrouther DA

PMID: 31442390 [PubMed - indexed for MEDLINE]

Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach.

dim, 10/05/2020 - 21:17
Related Articles

Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach.

Ann Rheum Dis. 2020 03;79(3):356-362

Authors: Hanly JG, Urowitz MB, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Clarke AE, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Fortin PR, Gladman DD, Bruce IN, Petri M, Ginzler EM, Dooley MA, Ramsey-Goldman R, Manzi S, Jönsen A, Alarcón GS, van Vollenhoven RF, Aranow C, Mackay M, Ruiz-Irastorza G, Lim S, Inanc M, Kalunian KC, Jacobsen S, Peschken CA, Kamen DL, Askanase A, Farewell V

Abstract
OBJECTIVES: Using a reversible multistate model, we prospectively examined neuropsychiatric (NP) events for attribution, outcome and association with health-related quality of life (HRQoL), in an international, inception cohort of systemic lupus erythematosus (SLE) patients.
METHODS: Annual assessments for 19 NP events attributed to SLE and non-SLE causes, physician determination of outcome and patient HRQoL (short-form (SF)-36 scores) were measured. Time-to-event analysis and multistate modelling examined the onset, recurrence and transition between NP states.
RESULTS: NP events occurred in 955/1827 (52.3%) patients and 592/1910 (31.0%) unique events were attributed to SLE. In the first 2 years of follow-up the relative risk (95% CI) for SLE NP events was 6.16 (4.96, 7.66) and non-SLE events was 4.66 (4.01, 5.43) compared with thereafter. Patients without SLE NP events at initial assessment had a 74% probability of being event free at 10 years. For non-SLE NP events the estimate was 48%. The majority of NP events resolved over 10 years but mortality was higher in patients with NP events attributed to SLE (16%) versus patients with no NPSLE events (6%) while the rate was comparable in patients with non-SLE NP events (7%) compared with patients with no non-SLE events (6%). Patients with NP events had lower SF-36 summary scores compared with those without NP events and resolved NP states (p<0.001).
CONCLUSIONS: NP events occur most frequently around the diagnosis of SLE. Although the majority of events resolve they are associated with reduced HRQoL and excess mortality. Multistate modelling is well suited for the assessment of NP events in SLE.

PMID: 31915121 [PubMed - indexed for MEDLINE]

Novel ultrasonographic Halo Score for giant cell arteritis: assessment of diagnostic accuracy and association with ocular ischaemia.

dim, 10/05/2020 - 21:17
Related Articles

Novel ultrasonographic Halo Score for giant cell arteritis: assessment of diagnostic accuracy and association with ocular ischaemia.

Ann Rheum Dis. 2020 03;79(3):393-399

Authors: van der Geest KSM, Borg F, Kayani A, Paap D, Gondo P, Schmidt W, Luqmani RA, Dasgupta B

Abstract
OBJECTIVES: Ultrasound of temporal and axillary arteries may reveal vessel wall inflammation in patients with giant cell arteritis (GCA). We developed a ultrasound scoring system to quantify the extent of vascular inflammation and investigated its diagnostic accuracy and association with clinical factors in GCA.
METHODS: This is a prospective study including 89 patients suspected of having GCA, of whom 58 had a confirmed clinical diagnosis of GCA after 6 months follow-up. All patients underwent bilateral ultrasound examination of the three temporal artery (TA) segments and axillary arteries, prior to TA biopsy. The extent of vascular inflammation was quantified by (1) counting the number of TA segments and axillary arteries with a halo and (2) calculating a composite Halo Score that also incorporated the thickness of each halo.
RESULTS: Halo counts and Halo Scores showed moderate diagnostic accuracy for a clinical diagnosis of GCA. They correlated positively with systemic inflammation. When compared with the halo count, the Halo Score correlated better with C-reactive protein (CRP) levels and allowed to firmly establish the diagnosis of GCA in more patients. Higher halo counts and Halo Scores were associated with a higher risk of ocular ischaemia. They allowed to identify subgroups of patients with low risk (≤5%) and high risk of ocular ischaemia (>30%).
CONCLUSIONS: Ultrasound halo scoring allows to quantify the extent of vascular inflammation in GCA. Extensive vascular inflammation on ultrasound may provide strong diagnostic confirmation and associates with ocular ischaemia in GCA.

PMID: 31900304 [PubMed - indexed for MEDLINE]

Risk of malignancy in patients treated for systemic necrotising vasculitis.

dim, 10/05/2020 - 21:17
Related Articles

Risk of malignancy in patients treated for systemic necrotising vasculitis.

Ann Rheum Dis. 2020 03;79(3):431-433

Authors: Lafarge A, Joseph A, Pagnoux C, Puechal X, Cohen P, Samson M, Hamidou M, Karras A, Groh M, Quemeneur T, Ribi C, Mouthon L, Guillevin L, Terrier B, French Vasculitis Study Group (FVSG)

PMID: 31767700 [PubMed - indexed for MEDLINE]

Rituximab for chronic periaortitis without evidence of IgG4-related disease: a long-term follow-up study of 20 patients.

dim, 10/05/2020 - 21:17
Related Articles

Rituximab for chronic periaortitis without evidence of IgG4-related disease: a long-term follow-up study of 20 patients.

Ann Rheum Dis. 2020 03;79(3):433-434

Authors: Urban ML, Maritati F, Palmisano A, Fenaroli P, Peyronel F, Trivioli G, Ferretti S, De Biase C, Grayson PC, Pegoraro F, Prisco D, Romagnani P, Emmi G, Vaglio A

PMID: 31744824 [PubMed - indexed for MEDLINE]

Psoriasis-associated progressive necrotizing posterior scleritis: A 6-year follow-up.

dim, 10/05/2020 - 21:17
Related Articles

Psoriasis-associated progressive necrotizing posterior scleritis: A 6-year follow-up.

Eur J Ophthalmol. 2020 May;30(3):NP7-NP10

Authors: Amer R, Levinger N

Abstract
PURPOSE: Posterior scleritis is the least frequent form of scleritis accounting for around 2%-8% of all scleritis cases. We aim to present the 6-year clinical course of a 62-year-old female patient with bilateral progressive necrotizing posterior scleritis who suffered from concurrent active psoriasis and psoriatic arthritis.
METHODS: Descriptive case report.
RESULTS: A middle-aged female patient was referred to our clinic because of left eye peripheral progressively enlarging white retinochoroidal lesions. Her previous work-up ruled out infectious and malignant etiologies. A second diagnostic vitrectomy was performed because of the slowly progressive and the atypical nature of the sectoral retinochoroidal patches in the retinal periphery. Again malignancy was ruled out. With the onset of cystoid macular edema and diffuse retinal vasculitis, which occurred concurrently with the reactivation of psoriasis and psoriatic arthritis, treatment was initiated with systemic immunosuppressants which initially included oral steroids and methotrexate and at the last follow-up 6 years after the first presentation included also cyclosporin and golimumab. Vision was preserved with quiescent uveitis and posterior scleritis.
CONCLUSION: Posterior scleritis is an uncommon condition and it is even rarer in the setting of psoriasis. The necrotizing inflammation observed in the present case and by others revealed sectoral progressive chorioretinitis as a clinical manifestation which may initially raise the suspicion of masquerade malignant and infectious etiologies. Detailed thorough history-taking remains the cornerstone in identifying the possible systemic associations even when occult or subclinical.

PMID: 30638053 [PubMed - indexed for MEDLINE]

Exuberant case of erythema elevatum diutinum in a patient infected with HIV and hepatitis B virus.

jeu, 07/05/2020 - 19:12
Related Articles

Exuberant case of erythema elevatum diutinum in a patient infected with HIV and hepatitis B virus.

An Bras Dermatol. 2020 Mar - Apr;95(2):200-202

Authors: Hirayama SA, Pinheiro CAT, Guarenti IM, Oliveira DS

Abstract
Erythema elevatum diutinum is a small vessel vasculitis which is benign, rare, and chronic. It is clinically characterized by violaceous, brown, or yellowish plaques, nodules, and papules. It has been associated with autoimmune, infectious, and neoplastic processes. The following case describes a patient with hepatitis B virus and human immunodeficiency virus with CD4 count<200mm3, HIV-seropositive for 16 years, and diagnosed with hepatitis B virus at the hospital. The patient was treated with oral dapsone 100mg/day, showing regression after seven months of treatment. The authors found three cases in the literature of association of erythema elevatum diutinum, human immunodeficiency virus, and hepatitis B virus.

PMID: 32173140 [PubMed - indexed for MEDLINE]

Normothermic and hypothermic oxygenated perfusion for donation after circulatory death in kidney transplantation: do we pay higher risk of severe infection after transplantation?: a case report.

jeu, 07/05/2020 - 19:12
Related Articles

Normothermic and hypothermic oxygenated perfusion for donation after circulatory death in kidney transplantation: do we pay higher risk of severe infection after transplantation?: a case report.

BMC Infect Dis. 2020 Feb 10;20(1):115

Authors: Ravaioli M, Corradetti V, Renzulli M, Germinario G, Maroni L, Odaldi F, Fallani G, Pezzuto AP, Parlanti D, Bova R, Bini C, La Manna G, Comai G

Abstract
BACKGROUND: Normothermic and hypothermic oxygenated perfusion for donation after circulatory death in kidney transplantation are becoming popular in Italy, with the purpose of reducing the risk of primary non function and delayed graft function due to the prolonged warm ischemia time. Potential complications related to these procedures are currently under investigation and are continuously emerging with the increasing experience. Post-operative infections - in particular graft arteritis - are a rare complication but determine high risk of mortality and of graft loss. The acute onset of the arterial complications makes it very difficult to find an effective treatment, and early diagnosis is crucial for saving both patient and graft. Prevention of such infections in this particular setting are advisable.
CASE PRESENTATION: We present a patient with an acute arterial rupture after transplantation of a DCD graft treated in-vivo hypothermic oxygenated perfusion. The cause was a severe arteritis of the renal artery caused by Candida krusei and Pseudomonas aeruginosa. We discussed our treatment and we compared it to the other reported series.
CONCLUSION: Fungal infections in DCD transplant may be treacherous and strategies to prevent them should be advocated.

PMID: 32041547 [PubMed - indexed for MEDLINE]

Response to 'IgA vasculitis in adults: few certainties and many uncertainties' by Hočevar et al.

jeu, 07/05/2020 - 19:12
Related Articles

Response to 'IgA vasculitis in adults: few certainties and many uncertainties' by Hočevar et al.

Ann Rheum Dis. 2020 04;79(4):e48

Authors: Tracy A, Subramanian A, Adderley NJ, Harper L, Nirantharakumar K

PMID: 30700428 [PubMed - indexed for MEDLINE]

IgA vasculitis in adults: few certainties and many uncertainties.

jeu, 07/05/2020 - 19:12
Related Articles

IgA vasculitis in adults: few certainties and many uncertainties.

Ann Rheum Dis. 2020 04;79(4):e47

Authors: Hočevar A, Tomšič M, Rotar Ž

PMID: 30612119 [PubMed - indexed for MEDLINE]

Severe infections in patients with anti-neutrophil cytoplasmic antibody-associated vasculitides receiving rituximab: A meta-analysis.

mar, 28/04/2020 - 12:13
Related Articles

Severe infections in patients with anti-neutrophil cytoplasmic antibody-associated vasculitides receiving rituximab: A meta-analysis.

Autoimmun Rev. 2020 May;19(5):102505

Authors: Thery-Casari C, Euvrard R, Mainbourg S, Durupt S, Reynaud Q, Durieu I, Belot A, Lobbes H, Cabrera N, Lega JC

Abstract
INTRODUCTION: The efficacy of rituximab (RTX) for remission induction and maintenance in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) is now established, but the safety, particularly concerning severe infection risk, is not well known.
OBJECTIVE: The purpose of this meta-analysis is to assess the prevalence and incidence of severe infections and the factors explaining heterogeneity in AAV patients treated with RTX.
METHODS: PubMed and Embase were searched up to December 2017. Prevalence and incidence was pooled using a random-effects model in case of significant heterogeneity (I2 > 50%). Severe infection was defined as severe when it led to hospitalization, intravenous antibiotics therapy, and/or death. The heterogeneity was explored by subgroup analyses and meta-regression.
RESULTS: The included studies encompassed 1434 patients with a median age of 51.9 years. The overall prevalence and incidence of severe infections was 15.4% (95% CI [8.9; 23.3], I2 = 90%, 33 studies) and 6.5 per 100 person-years (PY) (95% CI [2.9; 11.4], I2 = 76%, 18 studies), respectively. The most common infections were bacterial (9.4%, 95% CI [5.1; 14.8]). The prevalence of opportunistic infection was 1.5% (95% CI [0.5; 3.1], I2 = 58%) including pneumocytis jirovecii infections (0.2%, 95% CI [0.0; 0.6], I2 = 0), irrespective of prophylaxis administration. Mortality related to infection was estimated at 0.7% (95% CI [0.2; 1.2], I2 = 27%). The RTX cumulative dose was positively associated with prevalence of infections (13 studies, prevalence increase of 4% per 100 mg, p < .0001). The incidence of infection was negatively associated with duration of follow-up (8 studies, incidence decrease of 9% per year, p = .03).
CONCLUSION: Prevalence and incidence of severe infections, mainly bacterial ones, were high in AAV patients treated with RTX. This meta-analysis highlights the need for prospective studies to stratify infectious risk and validate cumulative RTX dose and duration of follow-up as modifying factors.

PMID: 32173512 [PubMed - indexed for MEDLINE]

Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis.

mar, 28/04/2020 - 12:13
Related Articles

Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis.

Ann Rheum Dis. 2020 02;79(2):225-231

Authors: Lee PY, Schulert GS, Canna SW, Huang Y, Sundel J, Li Y, Hoyt KJ, Blaustein RB, Wactor A, Do T, Halyabar O, Chang MH, Dedeoglu F, Case SM, Meidan E, Lo MS, Sundel RP, Richardson ET, Newburger JW, Hershfield MS, Son MB, Henderson LA, Nigrovic PA

Abstract
OBJECTIVE: Macrophage activation syndrome (MAS) is a life-threatening complication of systemic juvenile idiopathic arthritis (sJIA) characterised by a vicious cycle of immune amplification that can culminate in overwhelming inflammation and multiorgan failure. The clinical features of MAS overlap with those of active sJIA, complicating early diagnosis and treatment. We evaluated adenosine deaminase 2 (ADA2), a protein of unknown function released principally by monocytes and macrophages, as a novel biomarker of MAS.
METHODS: We established age-based normal ranges of peripheral blood ADA2 activity in 324 healthy children and adults. We compared these ranges with 173 children with inflammatory and immune-mediated diseases, including systemic and non-systemic JIA, Kawasaki disease, paediatric systemic lupus erythematosus and juvenile dermatomyositis.
RESULTS: ADA2 elevation beyond the upper limit of normal in children was largely restricted to sJIA with concomitant MAS, a finding confirmed in a validation cohort of sJIA patients with inactive disease, active sJIA without MAS or sJIA with MAS. ADA2 activity strongly correlated with MAS biomarkers including ferritin, interleukin (IL)-18 and the interferon (IFN)-γ-inducible chemokine CXCL9 but displayed minimal association with the inflammatory markers C reactive protein and erythrocyte sedimentation rate. Correspondingly, ADA2 paralleled disease activity based on serial measurements in patients with recurrent MAS episodes. IL-18 and IFN-γ elicited ADA2 production by peripheral blood mononuclear cells, and ADA2 was abundant in MAS haemophagocytes.
CONCLUSIONS: These findings collectively identify the utility of plasma ADA2 activity as a biomarker of MAS and lend further support to a pivotal role of macrophage activation in this condition.

PMID: 31707357 [PubMed - indexed for MEDLINE]

Clinical symptoms and associated vascular imaging findings in Takayasu's arteritis compared to giant cell arteritis.

mar, 28/04/2020 - 12:13
Related Articles

Clinical symptoms and associated vascular imaging findings in Takayasu's arteritis compared to giant cell arteritis.

Ann Rheum Dis. 2020 02;79(2):262-267

Authors: Michailidou D, Rosenblum JS, Rimland CA, Marko J, Ahlman MA, Grayson PC

Abstract
OBJECTIVE: To compare the presence of head, neck and upper extremity symptoms in patients with Takayasu's (TAK) and giant cell arteritis (GCA) and their association with vascular inflammation assessed by 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) or arterial damage assessed by magnetic resonance angiography (MRA).
METHODS: Patients with TAK and GCA underwent clinical and imaging assessments within 24 hours, blinded to each other. Vascular inflammation was defined as arterial FDG-PET uptake greater than liver by visual assessment. Arterial damage was defined as stenosis, occlusion, or aneurysm by MRA. Clinically reported symptoms were compared with corresponding imaging findings using generalised mixed model regression. Cranial symptoms were studied in association with burden of arterial disease in the neck using ordinal regression.
RESULTS: Participants with TAK (n=56) and GCA (n=54) contributed data from 270 visits. Carotidynia was reported only in patients with TAK (21%) and was associated with vascular inflammation (p<0.01) but not damage (p=0.33) in the corresponding carotid artery. Posterior headache was reported in TAK (16%) and GCA (20%) but was only associated with corresponding vertebral artery inflammation and damage in GCA (p<0.01). Arm claudication was associated with subclavian artery damage (p<0.01) and inflammation (p=0.04) in TAK and with damage in GCA (p<0.01). Patients with an increased burden of damaged neck arteries were more likely to experience positional lightheadedness (p<0.01) or a major central nervous system event (p=0.01).
CONCLUSION: The distribution of symptoms and association with imaging abnormalities differs in patients with TAK and GCA. These findings may help clinicians predict associated FDG-PET and MRA findings based on a specific clinical symptom.
CLINICAL TRIAL REGISTRATION NUMBER: NCT02257866.

PMID: 31649025 [PubMed - indexed for MEDLINE]

Colchicine therapy for deep vein thrombosis in a patient with vascular-type Behçet disease: A case report.

sam, 25/04/2020 - 09:21
Related Articles

Colchicine therapy for deep vein thrombosis in a patient with vascular-type Behçet disease: A case report.

Medicine (Baltimore). 2020 Apr;99(16):e19814

Authors: Nonaka D, Takase H, Machii M, Ohno K

Abstract
RATIONALE: Behçet Disease (BD) is a chronic inflammatory vasculitis with thrombogenicity and multisystem involvement. Deep vein thrombosis (DVT) in the lower extremities is the most frequent manifestation of vascular involvement in BD. The causes of thrombosis vary widely and include congenital predisposition and acquired factors, but of all the thrombosis, the cause is rarely BD. Furthermore, there are few reports of treatment for thrombosis in BD.
PATIENT CONCERNS: We herein describe the case of an Asian male patient aged 40 years, admitted to our hospital for left leg pain, edema, and swelling.
DIAGNOSES: We confirmed the DVT and pulmonary artery thrombosis (PAT) by contrast computed tomography angiogram. At the same time, the patient developed oral ulcerations and skin lesions consistent with BD.
INTERVENTIONS: The patient was initially treated with anticoagulants. However, because the improvement of DVT was inadequate, we added colchicine in anticipation of anti-inflammatory effects. After that, anticoagulation was discontinued, and only colchicine was continuously prescribed.
OUTCOMES: We observed an almost complete resolution of DVT and PAT with no recurrence of thrombosis for 6 months after discharge.
LESSONS: This case shows us that we should consider BD as a differential diagnosis of DVT and that colchicine therapy is effective for inflammation-induced thrombosis in BD.

PMID: 32312000 [PubMed - indexed for MEDLINE]

ANCA associated vasculitis.

sam, 25/04/2020 - 09:21
Related Articles

ANCA associated vasculitis.

BMJ. 2020 04 14;369:m1070

Authors: Hunter RW, Welsh N, Farrah TE, Gallacher PJ, Dhaun N

PMID: 32291255 [PubMed - indexed for MEDLINE]

Pages